Reavard Tamin Pharmaceutical Company (DAREAVAR) income statement
Operating revenue through to net profit and earnings per share
- Ticker
- DAREAVAR
- Industry
- Pharmaceuticals
- Market
- Iran Fara Bourse
Latest periods
| Item | To 1405/06/31 | To 1404/06/31 | To 1403/06/31 | To 1402/06/31 | To 1401/06/31 | To 1400/06/31 |
|---|---|---|---|---|---|---|
| Operating revenue | 8,494,691 | 6,249,402 | 4,395,651 | 3,881,476 | 1,781,547 | 1,107,134 |
| Cost of operating revenue | -3,850,726 | -2,913,694 | -1,893,999 | -2,091,349 | -638,918 | -472,522 |
| Gross profit (loss) | 4,643,965 | 3,335,708 | 2,501,652 | 1,790,127 | 1,142,629 | 634,612 |
| Selling, general and administrative expenses | -611,716 | -352,272 | -210,110 | -135,525 | -81,299 | -45,993 |
| Operating profit (loss) | 4,032,249 | 2,983,436 | 2,291,542 | 1,654,602 | 1,061,330 | 588,619 |
| Finance costs | -679,930 | -405,237 | -256,679 | -230,765 | -149,171 | -144,913 |
| Other non-operating income and expenses | -33,988 | 344,748 | 357,347 | 145,773 | 16,501 | 7,117 |
| Profit (loss) from continuing operations before tax | 3,318,331 | 2,922,947 | 2,392,210 | 1,569,610 | 928,660 | 450,823 |
| Current year tax | -746,624 | -538,116 | -587,489 | -259,703 | -127,221 | -89,665 |
| Net profit (loss) from continuing operations | 2,571,707 | 2,384,831 | 1,804,721 | 1,309,907 | 801,439 | 361,158 |
| Net profit (loss) | 2,571,707 | 2,384,831 | 1,804,721 | 1,309,907 | 801,439 | 361,158 |
| Basic earnings (loss) per share | 964 rials | 899 rials | 7,266 rials | 5,264 rials | 3,219 rials | 1,810 rials |
| Net earnings (loss) per share, rials | 962 rials | 892 rials | 7,219 rials | 5,240 rials | 3,206 rials | 1,806 rials |
| Capital | 2,675,294 | 2,675,294 | 250,000 | 250,000 | 250,000 | 200,000 |
Reporting periods
44 periods are on file for this report, from the period ending 1396/12/29 to the period ending 1405/06/31.